share_log

Needham Maintains Buy on Vir Biotechnology, Lowers Price Target to $15

Benzinga ·  Nov 3, 2023 07:22

Needham analyst Joseph Stringer maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and lowers the price target from $22 to $15.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment